LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.18
−2.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.21
From 52W high−80.68%
Volume44847.00
Market cap$17.93M
P/E (TTM)—
P/S (TTM)11.4x
Div yield—
Key dataSep 18, 2026
Open
$2.21
From 52W high
−80.68%
Volume
44847.00
Market cap
$17.93M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
43.7
MomentumView details →
1D Return
−2.03%
YTD Return
−73.38%
SummaryUpdated Jun 1, 2026
Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company founded and headquartered in Salt Lake City, Utah. The company went public in October 2013 and specializes in developing oral delivery solutions for pharmaceutical products that treat neuroendocrine and metabolic disorders. Lipocine's core focus is on creating oral formulations of drugs that traditionally have poor bioavailability when taken by mouth, particularly hormone-based therapies. The company's lead product, TLANDO, is an oral testosterone replacement therapy that has received FDA approval, representing a significant milestone in the company's development trajectory.
Similar companies
Latest newsMore news →
Lipocine Inc. announced the initiation of the BLOOM Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression, with first participant dosing expected in early Q4 2026.6d agoLipocine Inc. reported its Q2 2026 financial results, with revenue of $190,099 and a net loss of $2,622,595.48d ago